Gilead Sciences EPS beats by $0.22, beats on revenue
Gilead Sciences (NASDAQ:GILD): Q3 Non-GAAP EPS of $2.11 beats by $0.22; GAAP EPS of $0.29 misses by $0.96.
Revenue of $6.56B (+17.1% Y/Y) beats by $260M.
R&D expenses of $1.16B vs. $1.19B consensus.
FY20 EPS of $6.25-$6.60 from prior guidance of $6.25-$7.65 vs. $6.87 consensus.
Shares +0.6%.
https://seekingalpha.com/news/3627604-gi...on-revenue
Gilead Sciences (NASDAQ:GILD): Q3 Non-GAAP EPS of $2.11 beats by $0.22; GAAP EPS of $0.29 misses by $0.96.
Revenue of $6.56B (+17.1% Y/Y) beats by $260M.
R&D expenses of $1.16B vs. $1.19B consensus.
FY20 EPS of $6.25-$6.60 from prior guidance of $6.25-$7.65 vs. $6.87 consensus.
Shares +0.6%.
https://seekingalpha.com/news/3627604-gi...on-revenue
